AP911A - Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. - Google Patents

Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. Download PDF

Info

Publication number
AP911A
AP911A APAP/P/1998/001401A AP9801401A AP911A AP 911 A AP911 A AP 911A AP 9801401 A AP9801401 A AP 9801401A AP 911 A AP911 A AP 911A
Authority
AP
ARIPO
Prior art keywords
alkyl
mono
inhibitor
aldose reductase
glycogen phosphorylase
Prior art date
Application number
APAP/P/1998/001401A
Other languages
English (en)
Other versions
AP9801401A0 (en
Inventor
Banavara L Mylari
Denis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9801401A0 publication Critical patent/AP9801401A0/xx
Application granted granted Critical
Publication of AP911A publication Critical patent/AP911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Noise Elimination (AREA)
APAP/P/1998/001401A 1997-11-21 1998-11-19 Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. AP911A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (2)

Publication Number Publication Date
AP9801401A0 AP9801401A0 (en) 1998-12-31
AP911A true AP911A (en) 2000-12-07

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001401A AP911A (en) 1997-11-21 1998-11-19 Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor.

Country Status (38)

Country Link
EP (1) EP1032424B9 (xx)
JP (1) JP2002504478A (xx)
KR (2) KR20010032304A (xx)
CN (1) CN1279617A (xx)
AP (1) AP911A (xx)
AR (1) AR016423A1 (xx)
AT (1) ATE205403T1 (xx)
AU (1) AU733304B2 (xx)
BG (1) BG104435A (xx)
BR (1) BR9814698A (xx)
CA (1) CA2310069A1 (xx)
DE (1) DE69801680T2 (xx)
DK (1) DK1032424T3 (xx)
DZ (1) DZ2656A1 (xx)
EA (1) EA002365B1 (xx)
ES (1) ES2161548T3 (xx)
GR (1) GR3037071T3 (xx)
GT (1) GT199800166A (xx)
HR (1) HRP20000327A2 (xx)
HU (1) HUP0100272A3 (xx)
ID (1) ID24524A (xx)
IL (1) IL135713A0 (xx)
IS (1) IS5453A (xx)
MA (1) MA26568A1 (xx)
NO (1) NO20002164L (xx)
OA (1) OA11379A (xx)
PA (1) PA8462301A1 (xx)
PE (1) PE135399A1 (xx)
PL (1) PL340643A1 (xx)
PT (1) PT1032424E (xx)
SK (1) SK7222000A3 (xx)
TN (1) TNSN98211A1 (xx)
TR (1) TR200001451T2 (xx)
UA (1) UA57811C2 (xx)
UY (1) UY25258A1 (xx)
WO (1) WO1999026659A1 (xx)
YU (1) YU30700A (xx)
ZA (1) ZA9810636B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047206A1 (en) * 1999-02-12 2000-08-17 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
PT1689757E (pt) 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Compostos heterocíclicos de ácido borónico
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PT2173737E (pt) 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
EA201270755A1 (ru) 2010-04-08 2013-03-29 Бристол-Майерс Сквибб Компани Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624369A1 (en) * 1993-05-10 1994-11-17 Pfizer Inc. Method of lowering blood lipid levels
WO1996039385A1 (en) * 1995-06-06 1996-12-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
WO1996039384A1 (en) * 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624369A1 (en) * 1993-05-10 1994-11-17 Pfizer Inc. Method of lowering blood lipid levels
WO1996039385A1 (en) * 1995-06-06 1996-12-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
WO1996039384A1 (en) * 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
KR20010032304A (ko) 2001-04-16
YU30700A (sh) 2002-12-10
PE135399A1 (es) 2000-01-15
DE69801680D1 (de) 2001-10-18
TNSN98211A1 (fr) 2005-03-15
DK1032424T3 (da) 2001-11-19
KR100661214B1 (ko) 2006-12-26
SK7222000A3 (en) 2001-09-11
CN1279617A (zh) 2001-01-10
AR016423A1 (es) 2001-07-04
BG104435A (bg) 2001-01-31
AU9555898A (en) 1999-06-15
EA200000433A1 (ru) 2000-12-25
EP1032424A1 (en) 2000-09-06
UY25258A1 (es) 2000-12-29
AU733304B2 (en) 2001-05-10
KR20010032300A (ko) 2001-04-16
EA002365B1 (ru) 2002-04-25
GT199800166A (es) 2000-04-19
ID24524A (id) 2000-07-20
ATE205403T1 (de) 2001-09-15
BR9814698A (pt) 2000-10-03
ES2161548T3 (es) 2001-12-01
ZA9810636B (en) 2000-05-22
IL135713A0 (en) 2001-05-20
PA8462301A1 (es) 2000-05-24
OA11379A (en) 2004-01-28
NO20002164L (no) 2000-07-19
GR3037071T3 (en) 2002-01-31
NO20002164D0 (no) 2000-04-27
AP9801401A0 (en) 1998-12-31
PL340643A1 (en) 2001-02-12
HRP20000327A2 (en) 2001-02-28
TR200001451T2 (tr) 2002-06-21
MA26568A1 (fr) 2004-12-20
JP2002504478A (ja) 2002-02-12
IS5453A (is) 2000-04-14
WO1999026659A1 (en) 1999-06-03
HUP0100272A3 (en) 2002-11-28
DE69801680T2 (de) 2002-02-07
HUP0100272A2 (hu) 2001-06-28
EP1032424B1 (en) 2001-09-12
PT1032424E (pt) 2001-12-28
DZ2656A1 (fr) 2003-03-22
UA57811C2 (uk) 2003-07-15
EP1032424B9 (en) 2004-10-06
CA2310069A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
AP911A (en) Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor.
AU706628B2 (en) Treatment of arteriosclerosis and xanthoma
US7166625B2 (en) Method for treating fibrotic diseases and other indications
US20030027820A1 (en) Method for treating fibrotic diseases or other indications V
US20070043016A1 (en) Method of treating fibrotic diseases or other indications with imidazolium agents
ZA200608886B (en) Indolyl derivatives as liver-X-receptor modulators
ZA200607491B (en) Tetrahydrocarbazoles and derivatives
EA015169B1 (ru) Применение ингибиторов дипептидилпептидазы
JP2010248205A (ja) 強皮症の治療のためのベンザゾール誘導体
RU2448093C2 (ru) Производные пиридина для лечения метаболических нарушений, связанных с устойчивостью к действию инсулина или гипергликемией
CA2448294A1 (en) Method for treating fibrotic diseases or other indications vi
WO2006132196A1 (ja) β３作動薬を含有する新規な医薬
AU2002241670B2 (en) Method for treating glaucoma IB
JP2000086629A (ja) 新規な酸化窒素放出化合物
CA2448449A1 (en) Treatment of renal fibrosis
KR20080028382A (ko) 레닌 억제제와 인슐린 분비 증진제 또는 인슐린 증감제의조합물
KR20010108387A (ko) 당뇨병 치료제
CA2511735C (en) A method for treating renal failure using levosimendan or its metabolite or salts thereof
EP1370266A1 (en) Method of treatment
EP1864663A1 (en) Preventive and/or therapeutic agent for rheumatoid arthritis
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
CA2417883A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
Bell Drugs for cardiovascular risk reduction in the diabetic patient
CA3221533A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
AU2020298782A1 (en) Combination therapy methods, compositions and kits